← All trials
NCT05607004
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 30, 2022
- Primary completion
- Jan 31, 2025
- Completion date
- Jul 31, 2025
- First posted
- Nov 7, 2022
- Last posted
- Nov 14, 2022
- Enrollment
- 174
- Arms / groups
- 5 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Atossa Genetics, Inc.Lead sponsor
- Mayo ClinicOverall official - principal investigator
- InClin, Inc.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.